Systemic Treatment Options for Recurrent Head and Neck Squamous Cell Carcinoma
For first-line treatment of recurrent/metastatic HNSCC, pembrolizumab combined with platinum and 5-FU is the preferred regimen for all patients regardless of PD-L1 status, with pembrolizumab monotherapy reserved for those with CPS ≥1 (and particularly CPS ≥20) who can tolerate delayed response. 1
First-Line Treatment Algorithm
The 2023 ASCO guidelines establish a clear treatment hierarchy based on PD-L1 Combined Positive Score (CPS):
For CPS ≥1:
- Pembrolizumab monotherapy is an option, particularly for CPS ≥20 (median OS 14.9 months vs 10.7 months with cetuximab-chemotherapy) 1
- Pembrolizumab + platinum + 5-FU provides superior outcomes (median OS 13 months vs 10.7 months with cetuximab-chemotherapy) 1
For CPS <1:
- Pembrolizumab + platinum + 5-FU remains the preferred option (median OS 11.3 months) 1
- Cetuximab + platinum + 5-FU is an acceptable alternative (median OS 10.7 months) 1
Critical decision point: Choose chemoimmunotherapy over pembrolizumab monotherapy when rapid tumor reduction is clinically necessary, even in high CPS patients, as response rates to single-agent pembrolizumab remain only ~20% 1. The combination approach achieves higher response rates when urgent disease control is required.
Alternative First-Line Options:
For patients unable to tolerate immunotherapy or platinum-based regimens:
- Cetuximab + platinum + 5-FU (the historical EXTREME regimen) remains viable 2
- Non-platinum monotherapy (taxanes) for frail patients with poor performance status 3
Second-Line Treatment (Platinum-Refractory Disease)
Pembrolizumab or nivolumab should be offered to all patients with platinum-refractory recurrent/metastatic HNSCC, regardless of PD-L1 CPS status. 1
This recommendation is based on:
- CheckMate 141 (nivolumab): median OS 7.5 months vs standard therapy
- KEYNOTE-040 (pembrolizumab): median OS 8.4 months vs standard therapy
- Both demonstrated OS benefit independent of HPV status or PD-L1 expression 1
- Lower rates of grade 3-4 adverse events compared to chemotherapy 1
Beyond Second-Line:
For patients progressing after immunotherapy, advanced lines of systemic treatment remain reasonable options. Recent meta-analysis data show:
- PFS-6: 47% and PFS-12: 23%
- OS-6: 70% and OS-12: 41%
- These outcomes support offering further systemic therapy rather than best supportive care alone 4
Options include:
- Single-agent chemotherapy (taxanes, methotrexate)
- Cetuximab (if not previously used)
- Clinical trial enrollment
Key Clinical Considerations
Performance status is the most established prognostic marker in recurrent/metastatic HNSCC 3. For patients with poor performance status:
- Consider expectant observation or single-agent taxane therapy
- Avoid aggressive triple-therapy regimens
- Prioritize quality of life over response rates
HPV status does not alter treatment recommendations in the recurrent/metastatic setting, though meta-analyses suggest greater PD-1 inhibitor efficacy in smokers and HPV-negative patients 1.
Common Pitfalls to Avoid
Do not withhold PD-1 inhibitors based on PD-L1 status in platinum-refractory disease - both pembrolizumab and nivolumab show benefit regardless of CPS 1
Do not use pembrolizumab monotherapy in patients requiring rapid disease control - combination chemoimmunotherapy achieves higher response rates when urgent tumor reduction is needed 1
Do not assume futility after immunotherapy progression - subsequent lines of therapy can still provide meaningful survival benefit (OS-12 of 41%) 4
Do not use triple cytotoxic regimens as standard - no single cytotoxic regimen demonstrates superior overall survival, and toxicity must be balanced against benefit 3